Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
Torbjörn Ström,1 Gordana Kozlovacki,2 Peter Myrenfors,1 Martin Almquist3 1Medical Department, Ipsen AB, Stockholm, Sweden; 2Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden; 3Department of Endocrine and Sarcoma Surgery, Lund Univers...
Main Authors: | Ström T, Kozlovacki G, Myrenfors P, Almquist M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-10-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/patient-and-nurse-experience-of-using-somatostatin-analogues-to-treat--peer-reviewed-article-PPA |
Similar Items
-
Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa
by: Daleen Geldenhuys, et al.
Published: (2020-10-01) -
Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
by: Aadil Adnan, et al.
Published: (2023-06-01) -
Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors
by: Paragliola RM, et al.
Published: (2016-10-01) -
Role of Somatostatin Signalling in Neuroendocrine Tumours
by: Olesja Rogoza, et al.
Published: (2022-01-01) -
P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
by: Kirstine Nielsen, et al.
Published: (2020-01-01)